Renowned Myeloma Expert Joins Mount Sinai--Bart Barlogie, MD, to serve as Director of Mulitple Myeloma Research
Bart Barlogie, MD, world-renowned myeloma expert who introduced the first curative therapy, a multi-drug regimen known as Total therapy 3, for multiple myeloma, joins the faculty of Tisch Cancer Institute of the Icahn School of Medicine at Mount Sinai (ISMM), one of the elite cancer centers designated by the National Cancer Institute (NCI). Dr. Barlogie will serve as director of research in the Myeloma Program led by Sundar Jagannath, MD, Professor of Hematology and Medical Oncology at ISMM.
“We are extremely excited for Dr. Barlogie to join us as he brings a wealth of expertise and innovation in myeloma research,” said Steven Burakoff, MD, Lillian and Henry M. Stratton Professor of Cancer Medicine and Director of The Tisch Cancer Institute at Mount Sinai. “With him and Dr. Jagannath at the helm, Mount Sinai will have the country’s premier myeloma program.”
"I am thrilled to join Mount Sinai and collaborate once again with my good friend and colleague, Dr. Sundar Jagannath,” said Dr. Barlogie. “I am excited to collaborate with Sundar and other elite scientists to find novel approaches for patients with high-risk myeloma. We have a unique opportunity to move the field forward, and our understanding of the underlying mechanisms in the transition to malignant disease.”
Dr. Barlogie's work has focused on biological and therapeutic research, including chemotherapy, immunotherapy and hematopoietic stem cell transplantation. Among his seminal contributions are the developments of the VAD regimen for refractory myeloma, autologous stem cell supported high dose therapy, tandem transplants, and thalidomide. Many new biological insights have been gained through Dr. Barlogie’s research, notably the identification of chromosome 13 deletions as a separate high-risk entity in myeloma, and more recently, the identification of distinct risk-stratified subgroups of myeloma.
Prior to joining Mount Sinai, Dr. Barlogie served for 20 years as director of Myeloma Institute for Research & Therapy at University of Arkansas for Medical Sciences (UAMS) and institute he founded. Under his leadership, the Institute became a world-renowned program and was recently awarded a $10 million grant to create the Bart Barlogie Center for Molecular Diagnostics and the Celgene Distinguished Endowed Chair in Molecular Therapeutics at UAMS.
Dr. Barlogie was educated in Germany and earned his post-graduate degrees at Heidelberg University and the Max Planck Institute for Medical Research. Following residency at the Universities of Munich and Muenster, he joined MD Anderson Hospital and Tumor Research Institute as a fellow. Dr. Barlogie's initial laboratory investigation was dedicated to studying tumor cell cycle kinetics and its implications for designing combination chemotherapy.
Dr. Barlogie is a Fellow of the American College of Physicians and has served on the Board of Directors of the International Myeloma Foundation. He has received numerous honors including the prestigious Jan Waldenstrom Award, the Celgene Career Achievement Award in Hematology Research, a Robert A. Kyle Lifetime Achievement Award from the International Myeloma Foundation, and the National Physician of the Year award for Clinical Excellence from Castle Connolly Medical Ltd.
Dr. Barlogie has published extensively, including more than 526 peer reviewed journal articles including four in the New England Journal of Medicine and 75 book chapters. He currently serves on the editorial boards of Annals of Hematology, Blood, Clinical and Experimental Medicine, Clinical Cancer Research, Clinical Lymphoma & Myeloma, Current Cancer Therapy Reviews, Clinical Myeloma, International Journal of Clinical Oncology, Oncologie and The Oncologist.
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with more than 43,000 employees working across eight hospitals, over 400 outpatient practices, nearly 300 labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time — discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 7,300 primary and specialty care physicians; 13 joint-venture outpatient surgery centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and more than 30 affiliated community health centers. We are consistently ranked by U.S. News & World Report's Best Hospitals, receiving high "Honor Roll" status, and are highly ranked: No. 1 in Geriatrics and top 20 in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Neurology/Neurosurgery, Orthopedics, Pulmonology/Lung Surgery, Rehabilitation, and Urology. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 12 in Ophthalmology. U.S. News & World Report’s “Best Children’s Hospitals” ranks Mount Sinai Kravis Children's Hospital among the country’s best in several pediatric specialties.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.